What BMI Qualifies for GLP-1 Treatment in India?

Quick answer: Eligibility is a clinical judgement, not a single number. Asian populations develop metabolic disease at lower BMIs than European populations — a WHO expert consultation identified 23 kg/m² as a public-health action point rather than the conventional 25. A proper assessment weighs BMI alongside waist circumference, blood glucose, lipids and existing conditions.

Why the Western BMI chart misleads Indians

BMI was derived from European populations, and it travels badly. At the same BMI, South Asians carry more body fat and less lean muscle than white European counterparts, and a systematic review found South Asians store more liver and abdominal fat at a given BMI.

The practical consequence is the "thin-fat" pattern many Indian clinicians see daily: someone with a BMI of 24, technically "normal" on a Western chart, who already has insulin resistance, fatty liver and a worrying lipid profile.

The numbers that matter more than BMI

Waist circumference is often the more informative measurement, because it approximates visceral fat — the metabolically active fat around the organs that drives insulin resistance, rather than the subcutaneous fat you can pinch.

Two people with an identical BMI can have very different visceral fat, and therefore very different risk. This is why an assessment that only weighs you is an incomplete assessment.

What a real eligibility assessment covers

• BMI and waist circumference together
• Fasting glucose and HbA1c — is there prediabetes or undiagnosed diabetes?
• Lipid profile and blood pressure
• Thyroid function, since hypothyroidism affects weight and needs treating in its own right
• Liver markers, given how common fatty liver is in India
• Personal and family history, including gallbladder disease and thyroid cancer
• Current medications, particularly insulin or sulfonylureas
• Whether you are planning a pregnancy

Weight is not the only reason to treat

Several obesity-related conditions have their own evidence for GLP-1 therapy. Semaglutide reduced major adverse cardiovascular events by 20% in people with overweight or obesity and established cardiovascular disease in the SELECT trial. Tirzepatide improved obstructive sleep apnoea in SURMOUNT-OSA. Semaglutide reduced knee osteoarthritis pain in STEP 9.

If you have one of these conditions, the calculation is different from pure weight management — and worth raising specifically.

When GLP-1 therapy is not the answer

These medicines are not for cosmetic weight loss in people at a healthy weight. They are not appropriate in pregnancy. And they are not a substitute for treating an underlying cause: if undiagnosed hypothyroidism is driving your weight gain, the thyroid needs treating first.

It is also worth knowing that lifestyle intervention alone has strong evidence in the right context. The Diabetes Prevention Program showed lifestyle change reduced progression to type 2 diabetes by 58% in people at high risk. Many people are appropriately treated without medication at all.

What to do with this

If your BMI is above 23 and you have any metabolic marker drifting — rising fasting glucose, a growing waist, fatty liver on a scan, a family history of diabetes — that is worth a proper assessment rather than a wait-and-see. Indian metabolic risk starts earlier than most charts suggest, and the earlier it is addressed, the more options exist.